Symbols

NVCR

Novocure·NASDAQ

--(--)

NVCR Profile

Novocure Limited

A global oncology company that develops novel therapy for the treatment of solid tumor cancers including glioblastoma brain cancer

Industry

Healthcare Equipment and Supplies

Established Date

02/11/2000

Listing Date

10/02/2015

Exchange

NASDAQ Stock Exchange

Full-time Employees

1,605

Fiscal Year Ends

12-31

Website

www.novocure.com

Security Type

Common stock

Office address

No. 4 The Forum, Grenville Street, St. Helier, Jersey JE2 4UF

Business

Introduction

Novocure Limited is a public limited liability company incorporated on 11 February 2000 under the laws of Jersey, Channel Islands. It is a global oncology company that has developed a proprietary platform technology known as Tumor Therapy Fields (TTFields), which uses electric fields to kill cancer cells. NovoCure's key commercial products include Optune Gio, Optune Lua and Optune Pax, which provide TTFields therapy through medical devices. The company's main focus is to drive commercial adoption of its products, obtain regulatory approval for new indications, and advance clinical programs aimed at improving overall survival in aggressive cancers. NovoCure sells its products in several countries, and a large portion of its revenue comes from markets in the United States, Germany, France and Japan.